Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RP-G28 in lactose intolerance
NCT01113619Phase 2Completed
- Sponsor
- Ritter Pharmaceuticals
- Start
- Apr 2011
- Primary completion
- Oct 2011
- Modality
- Microbiome Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of galacto-oligosaccharides in lactose intolerance (2 arms), sponsored by Ritter Pharmaceuticals. Primary endpoints: Change from Baseline in breath hydrogen production on Hydrogen Breath Test at 36 days and Change from Baseline in lactose intolerance symptom assessment during lactose challenge at 36 days. Started Apr 2011; status: completed.
02
Drugs
galacto-oligosaccharides
03
Conditions
lactose intolerance
Beyond the preview
Go deeper on NCT01113619.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01113619.